276 related articles for article (PubMed ID: 20639901)
1. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Sakamoto K; Triplett AA; Schuler LA; Wagner KU
Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
[TBL] [Abstract][Full Text] [Related]
2. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
3. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.
Muraoka-Cook RS; Sandahl M; Hunter D; Miraglia L; Earp HS
Mol Endocrinol; 2008 Oct; 22(10):2307-21. PubMed ID: 18653779
[TBL] [Abstract][Full Text] [Related]
4. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.
Wagner KU; Rui H
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):93-103. PubMed ID: 18228120
[TBL] [Abstract][Full Text] [Related]
5. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.
Dagvadorj A; Collins S; Jomain JB; Abdulghani J; Karras J; Zellweger T; Li H; Nurmi M; Alanen K; Mirtti T; Visakorpi T; Bubendorf L; Goffin V; Nevalainen MT
Endocrinology; 2007 Jul; 148(7):3089-101. PubMed ID: 17412813
[TBL] [Abstract][Full Text] [Related]
6. Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways.
Neilson LM; Zhu J; Xie J; Malabarba MG; Sakamoto K; Wagner KU; Kirken RA; Rui H
Mol Endocrinol; 2007 Sep; 21(9):2218-32. PubMed ID: 17550976
[TBL] [Abstract][Full Text] [Related]
7. Impaired alveologenesis and maintenance of secretory mammary epithelial cells in Jak2 conditional knockout mice.
Wagner KU; Krempler A; Triplett AA; Qi Y; George NM; Zhu J; Rui H
Mol Cell Biol; 2004 Jun; 24(12):5510-20. PubMed ID: 15169911
[TBL] [Abstract][Full Text] [Related]
8. Zinc Finger Homeodomain Factor Zfhx3 Is Essential for Mammary Lactogenic Differentiation by Maintaining Prolactin Signaling Activity.
Zhao D; Ma G; Zhang X; He Y; Li M; Han X; Fu L; Dong XY; Nagy T; Zhao Q; Fu L; Dong JT
J Biol Chem; 2016 Jun; 291(24):12809-12820. PubMed ID: 27129249
[TBL] [Abstract][Full Text] [Related]
9. Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Sakamoto K; Lin WC; Triplett AA; Wagner KU
Cancer Res; 2009 Aug; 69(16):6642-50. PubMed ID: 19638583
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis.
Caffarel MM; Zaragoza R; Pensa S; Li J; Green AR; Watson CJ
Cell Death Differ; 2012 Mar; 19(3):511-22. PubMed ID: 21941370
[TBL] [Abstract][Full Text] [Related]
11. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
12. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells.
Sakamoto K; Creamer BA; Triplett AA; Wagner KU
Mol Endocrinol; 2007 Aug; 21(8):1877-92. PubMed ID: 17519353
[TBL] [Abstract][Full Text] [Related]
13. Interactions among Janus kinases and the prolactin (PRL) receptor in the regulation of a PRL response element.
Gao J; Hughes JP; Auperin B; Buteau H; Edery M; Zhuang H; Wojchowski DM; Horseman ND
Mol Endocrinol; 1996 Jul; 10(7):847-56. PubMed ID: 8813725
[TBL] [Abstract][Full Text] [Related]
14. PRL/PRLR Can Promote Insulin Resistance by Activating the JAK2/STAT5 Signaling Pathway.
Wang PY; Jin CC; Liu C; Zhao ZJ; Yang HY
Comput Math Methods Med; 2022; 2022():1456187. PubMed ID: 36238467
[TBL] [Abstract][Full Text] [Related]
15. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
16. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase 2 (JAK2) regulates prolactin-mediated chloride transport in mouse mammary epithelial cells through tyrosine phosphorylation of Na+-K+-2Cl- cotransporter.
Selvaraj NG; Omi E; Gibori G; Rao MC
Mol Endocrinol; 2000 Dec; 14(12):2054-65. PubMed ID: 11117534
[TBL] [Abstract][Full Text] [Related]
18. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
19. Induction of multidrug resistance transporter ABCG2 by prolactin in human breast cancer cells.
Wu AM; Dalvi P; Lu X; Yang M; Riddick DS; Matthews J; Clevenger CV; Ross DD; Harper PA; Ito S
Mol Pharmacol; 2013 Feb; 83(2):377-88. PubMed ID: 23150485
[TBL] [Abstract][Full Text] [Related]
20. The last proline of Box 1 is essential for association with JAK2 and functional activation of the prolactin receptor.
Pezet A; Buteau H; Kelly PA; Edery M
Mol Cell Endocrinol; 1997 May; 129(2):199-208. PubMed ID: 9202403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
